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Figure 1. Lemann Index in Crohn’s disease patients at 2 time points.
(DLI=2.2, z=3.309, p=0.001) and significant changes in treatment
(DLI=2.2, z=2.418, p=0.016) during the interval period (Wilcoxon
signed-rank test, Figure 1).
Conclusions: Our results show that ongoing Crohn’s disease activity
as indicated by persistent symptomatic disease, persistent CRP eleva-
tion, frequent steroid use and changes in treatment is associated with
progressive bowel damage.
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Background: In children and adolescents with inflammatory bowel
disease (IBD) in clinical remission, it is difficult to predict when a
relapse will occur. Reliable data on the value of biomarkers of in-
flammation for predicting relapse in these young patients are lack-
ing. Therefore, we aimed to investigate the predictive value of fecal
calprotectin (FC) and CRP for symptomatic relapse in pediatric IBD
in clinical remission.
Methods: In this cross-sectional cohort study, patients aged <18
years with Crohn’s disease or ulcerative colitis in clinical remission
≥3 months were included. At baseline, clinical and biochemical dis-
ease activity were assessed using the abbreviated-Pediatric Crohn’s
Disease Activity Index (aPCDAI) or Pediatric Ulcerative Colitis Ac-
tivity Index (PUCAI), and FC and CRP, respectively. Clinical remis-
sion was defined as an aPCDAI or PUCAI <10. Disease course over
the subsequent 12 months was retrospectively assessed. Symptomatic
relapse was defined as an aPCDAI or PUCAI score ≥10, with the
need for treatment intensification. Multivariate Cox regression anal-
ysis was performed to evaluate whether FC and CRP were indepen-
dent predictors for symptomatic relapse.
Results: In total, 114 patients in clinical remission were included
(56% males; median age 14.9 years). Baseline FC level was higher
in patients that developed a relapse compared to patients without
symptomatic relapse (median 367 μg/g vs. 117μg/g, p=0.014). FC
level was an independent predictor for symptomatic relapse within 6
months from baseline (HR per 100μg/g: 1.15 [95% CI: 1.06–1.24],
p<0.001), corresponding to a 15% increase in the probability of re-
lapse per 100 μg/g increment, with fair predictive accuracy (AUC:
0.77, p<0.001). The optimal FC cut-off was 350 μg/g, with a sensi-
tivity and specificity of 76% and 78%, respectively.
Baseline CRP level did not differ between patients with or without
symptomatic relapse. CRP level was an independent predictor for
symptomatic relapse within 6 months from baseline (HR per 1mg/L:
1.10 [95% CI: 1.01–1.19], p=0.025), corresponding to a 10% in-
crease in the probability of relapse per 1 1mg/L increment, with poor
predictive accuracy (AUC: 0.67, p=0.036). The optimal CRP cut-off
was 0.6 mg/L, with a sensitivity and specificity of 88% and 38%,
respectively.
Conclusions: Levels of FC and CRP were both independent predic-
tors of symptomatic relapse in pediatric IBD in clinical remission,
with superior predictive test characteristics of FC. High FC levels at
routine measurement justify careful disease monitoring and evalua-
tion of current treatment.
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Background: There is no symptom-based patient-reported outcomes
(PRO) measurement available in IBD. Disease scores contain a mix-
ture of PRO and physician’s observations and have shown serious
limitations in clinical trials. Comparison between healthcare profes-
sionals (HCP) and patient (P) reports on scores’ items is a first step
toward disease scores refinement. In our IBD cohort study, we were
able to collect P and HCP-reported symptoms independently. We as-
sessed the agreement between both measures, and tested the corre-
lation between the general well-being item (GWB) and two health-
related quality of life (HRQoL) measures.
Methods: Between 2012 and 2015, we collected CDAI and MTWAI
items 1) during follow-up medical visits, 2) through P self-reported
follow-up questionnaire, except lab values. We compared items in-
dependently reported by HCP and P, stratified by diagnostic and
t HCP-P reports. We calculated the Cohen’s kappa (κ) statistic for
agreement. A quadratic weight was applied for more severely serious
disagreements. For EIM & complications, we computed a pooled κ
based on the average between observed and expected probability of
agreement over sub-items. A pooled κ was computed to summarize
agreement over all examined variables. We also collected SF-36 and
IBDQ scores. Pearson correlation coefficients r were calculated be-
tween both scores and GWB reports of HCP and P.
Results: 2427 reports could be evaluated (t: 537<1 month, 390
1–2, 1500 2–6), referring to 1385 patients (52% females, 58% CD).
The best overall κ was found at t 1–2 months, moderate for num-
ber of stools/wk and antidiarrheal treatment (AT) in CD, moderate
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Abstract P298 – Table 1. Cohen’s Kappa scores for GI-P agreement among activity index items (0–0.2: very low, 0.2–0.4: low, 0.4–0.6: moderate, 0.6–0.8:
high, 0.8–1: perfect).
to good for nocturnal diarrhea and bloody stools in UC. Agreement
on GWB was low to very low. P-reported GWB were well corre-
lated with IBDQ (CD: r=0.65, UC: r=0.67), SF-36 physical (PCS)
(CD: r=0.52, UC: r=0.58) an SF-36 mental (MCS) component scores
(CD: r=0.47, UC: r=0.46). Correlation of PCS resp. IBQDwith HCP-
reported CD-GBWwas moderate at t <1 and 2–3 months (r=−0.45
and −0.53, resp. −0.43 and −0.48), but correlation with MCS re-
mained low (r<0.40) whatever t. For UC, HCP-reported GBW
moderately correlated with IBDQ at t<1 and 1–2 months (r=−0.48
and −0.47), but was low when t >2. Correlation with PCS and
MCS remained low whatever t.
Conclusions: The agreement was low for many scores’ items, except
two per disease. Among scores’ items with high weight, eg CDAI AT
or GWB, agreement was surprisingly low. P-GWB correlated with
HRQoL scores better than HCP, especially for scores related to men-
tal or emotional aspects.
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Background: Ulcerative Colitis (UC) is associated with high rate of
morbidity and disability. There is an urgent unmet need to identify
a specific biomarker that early in the disease course select suitable
patients for appropriate therapy, avoiding thereby unnecessary step-
up therapies and patients’disability due to prolonged inflammation.
Recently, we showed that aberrant glycosylation of T cells plays a
crucial role in UC pathogenesis [1,2]. We herein studied whether this
molecular marker is able to predict therapy response in UC patients,
early in disease course.
Methods: 131 formalin fixed paraffin-embedded colonic biopsies
collected at the time of diagnosis from 131 UC patients were an-
alyzed by immunohistochemistry in order to evaluate the expres-
sion of our biomarker (glycosylation levels in intestinal T cells).
The relationship between biomarker expression and clinicopatholog-
ical/therapeutic features of UC patients was analyzed. ROC curves
were performed and the predictive value of the biomarker in the re-
sponse to therapy was determined.
Results: Univariate analysis showed that our biomarker is able to
predict patients’ therapeutic outcome, early in disease course, by dis-
tinguishing patients that will display a stable disease course (always
under 5-ASA) from those that will step-up therapy. High levels of
biomarker expression, at/near to diagnosis can predict 78% (Nega-
tive Predictive Value - NPV) of the patients that will display a good
disease course (always under 5ASA; p<0.05). When the biomarker
is analyzed in severe UC patients (MayoE 3) at diagnosis, the sen-
sitivity of the biomarker increase (from 46% to 64%), in which
low levels of biomarker are able to predict 78% (Postive Predic-
tive Value - PPV) of the UC patients that will step-up therapy to
biologics (with bad disease course). Multivariate analysis revealed
that only our biomarker and C Reactive Protein are shown to be
independent predictors of non-response to standard therapy (5ASA;
corticosteroids; immunomodulators). Interestingly, the ROC curve
(AUC=0.714, p=0.001) revealed a powerful effect of both molecular
parameters when analyzed together, suggesting an additive value in
the prediction of the failure to standard therapy. This additive predic-
tive effect was stronger when analyzed in severe patients (MayoE 3)
in which the association of both biomarkers is able to predict 70%
of the UC patients (PPV), early in the disease course, that will not
respond to standard therapy.
Conclusions: Our results reveal a potential novel molecular tool in
the prediction of failure to standard therapy in UC patients with
promising prognostic value to be included in the algorithm of the
therapy-decision making of UC patients.
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